Chung, D.Y.; Kang, D.H.; Kim, J.W.; Kim, D.K.; Lee, J.Y.; Hong, C.H.; Cho, K.S.
Does an Alternative Sunitinib Dosing Schedule Really Improve Survival Outcomes Over a Conventional Dosing Schedule in Patients with Metastatic Renal Cell Carcinoma? An Updated Systematic Review and Meta-Analysis. Cancers 2019, 11, 1830.
https://doi.org/10.3390/cancers11121830
AMA Style
Chung DY, Kang DH, Kim JW, Kim DK, Lee JY, Hong CH, Cho KS.
Does an Alternative Sunitinib Dosing Schedule Really Improve Survival Outcomes Over a Conventional Dosing Schedule in Patients with Metastatic Renal Cell Carcinoma? An Updated Systematic Review and Meta-Analysis. Cancers. 2019; 11(12):1830.
https://doi.org/10.3390/cancers11121830
Chicago/Turabian Style
Chung, Doo Yong, Dong Hyuk Kang, Jong Won Kim, Do Kyung Kim, Joo Yong Lee, Chang Hee Hong, and Kang Su Cho.
2019. "Does an Alternative Sunitinib Dosing Schedule Really Improve Survival Outcomes Over a Conventional Dosing Schedule in Patients with Metastatic Renal Cell Carcinoma? An Updated Systematic Review and Meta-Analysis" Cancers 11, no. 12: 1830.
https://doi.org/10.3390/cancers11121830
APA Style
Chung, D. Y., Kang, D. H., Kim, J. W., Kim, D. K., Lee, J. Y., Hong, C. H., & Cho, K. S.
(2019). Does an Alternative Sunitinib Dosing Schedule Really Improve Survival Outcomes Over a Conventional Dosing Schedule in Patients with Metastatic Renal Cell Carcinoma? An Updated Systematic Review and Meta-Analysis. Cancers, 11(12), 1830.
https://doi.org/10.3390/cancers11121830